Daily Cardiology Research Analysis
Analyzed 176 papers and selected 3 impactful papers.
Summary
Three impactful advances span mechanistic, therapeutic, and digital cardiology. A Nature Communications study reveals chitinase-like proteins enzymatically de-N-glycosylate CD36 to drive foam cell formation, offering an antibody-amenable target in atherosclerosis. A Nature report shows engineered immunosuppressive dendritic cells can protect against cardiac remodeling, while a large NPJ Digital Medicine study demonstrates personalized AI-ECG estimation of LVEF at scale with high accuracy for screening systolic dysfunction.
Research Themes
- Immunometabolism and glycoprotein editing in atherosclerosis
- Engineered cell immunotherapy to prevent cardiac fibrosis/remodeling
- AI-enabled, personalized ECG analytics for LV function screening
Selected Articles
1. Chitinase-like proteins de-N-glycosylating CD36 modify cholesterol metabolism in atherosclerotic macrophages.
This study uncovers that CHIL3/CHI3L2 act as glycosidases to de-N-glycosylate CD36 at N220/N321, boosting lipid uptake, activating mTOR, suppressing PPARγ, and impairing ABCG1-mediated efflux—thereby driving foam cell formation and atherogenesis. Neutralizing CHI3L2 prevented and treated atherosclerosis, nominating a druggable CLP–CD36 axis.
Impact: Identifies a previously unrecognized enzymatic mechanism linking glycoprotein editing of CD36 to foam cell biology and demonstrates antibody-based disease modification in vivo.
Clinical Implications: CHI3L2 may serve as a therapeutic target and biomarker in atherosclerosis; anti-CHI3L2 therapy could complement lipid-lowering to reduce plaque progression and destabilization.
Key Findings
- CHIL3/CHI3L2 bind CD36 and enzymatically de-N-glycosylate it (notably at N220 and N321), enhancing lipid uptake in macrophages.
- Increased lipid influx activates mTOR, induces proinflammatory reprogramming, suppresses PPARγ, and impairs ABCG1-mediated cholesterol efflux.
- Single-cell sequencing shows expansion of foamy macrophages and VSMC transdifferentiation to foam/osteoblast-like cells in plaques.
- Neutralizing CHI3L2 antibodies both prevented and treated atherosclerosis in vivo.
Methodological Strengths
- Multi-modal mechanistic validation (biochemistry, single-cell sequencing, functional macrophage assays).
- In vivo efficacy with neutralizing antibodies demonstrating prevention and treatment.
- Clear target engagement via defined CD36 glycosylation sites.
Limitations
- Preclinical models; human translational validation and safety of chronic CLP inhibition remain to be established.
- Potential off-target effects of glycosidase activity and long-term immunometabolic consequences are unknown.
Future Directions: Validate CHI3L2 as a biomarker/target in human cohorts; develop clinically viable antagonists/antibodies; assess synergy with statins/PCSK9i; evaluate plaque stabilization in large animals and early-phase trials.
Polymorphisms of mouse chitinase-like protein 3 (Chil3), a member of the mammalian chitinase-like protein (CLP) family, have been demonstrated to be associated with inflammatory diseases by regulating lipid metabolism. However, the specific immunomodulatory impacts of CLPs, mainly mouse CHIL3 and its human functional homologue chitinase-3-like 2 (CHI3L2), on macrophage cholesterol metabolism and atherosclerosis have remained unclear. Here, we find CLPs (CHIL3 and CHI3L2) accelerate atherogenesis in a macrophage-dependent manner. Mechanistically, we identify an autocrine mechanism through which CLPs regulate cholesterol metabolism in macrophages. Macrophage-secreted CLPs exacerbate lipid uptake by binding to CD36. CLPs exhibit glycosidase activity, targeting and hydrolyzing N-glycosylated glycans on CD36, predominantly at sites N220 and N321, thereby enhancing lipid uptake. Increased lipid influx activates mTOR in macrophages, driving their transition to a pro-inflammatory phenotype while simultaneously suppressing peroxisome proliferator-activated receptor gamma (PPARγ) expression and thus impairing ABCG1-mediated cholesterol efflux. Single-cell sequencing reveals that CLPs increase atherosclerotic foamy macrophages, favoring vascular smooth muscle cells (VSMC) transformation into foam and osteoblast-like cells. Additionally, neutralizing antibodies targeting CHI3L2 prevent and treat atherosclerosis. These findings highlight the potential of CLPs as targets for disease diagnosis and therapy.
2. Engineered immunosuppressive dendritic cells protect against cardiac remodelling.
This study demonstrates that engineered immunosuppressive (tolerogenic) dendritic cells can protect against pathological cardiac remodeling, addressing the unmet need to prevent or reverse fibrosis-driven heart failure progression.
Impact: Introduces a cell-based immunotherapy paradigm to directly modulate profibrotic cardiac immune pathways and prevent remodeling.
Clinical Implications: If translated, tolerogenic dendritic cell therapy could offer disease-modifying treatment for heart failure by targeting fibrosis rather than purely symptomatic relief.
Key Findings
- Engineered immunosuppressive dendritic cells protected against cardiac remodeling.
- Findings address the lack of therapies that prevent or reverse pathological fibrosis and functional decline.
Methodological Strengths
- Conceptual innovation introducing engineered tolerogenic dendritic cells for cardiac protection.
- Preclinical demonstration of anti-remodeling efficacy.
Limitations
- Details on models, dosing, and durability are not specified in the provided text; clinical translatability remains to be established.
- Safety, manufacturability, and scalability of cell therapy require rigorous evaluation.
Future Directions: Define mechanisms of immune modulation, optimize dosing/manufacturing, and evaluate safety/efficacy in large animals and early-phase clinical trials.
Heart failure remains a leading cause of morbidity and mortality, yet no approved therapies effectively prevent or reverse pathological cardiac fibrosis and the associated decline in cardiac function
3. Personalized artificial intelligence based left ventricular ejection fraction and systolic dysfunction assessment.
In 191,941 patients (236,623 ECG/TTE pairs), AI models estimated LVEF from ECG with MAE ~7.7%, improving to ~6.0% using personalized approaches. For LVEF ≤40%, the model achieved AUC 0.88, sensitivity 0.92, and NPV 0.98, supporting ECG-first triage for systolic dysfunction.
Impact: Demonstrates scalable, personalized AI-ECG for LV function estimation with high negative predictive value, enabling low-cost population screening and care navigation.
Clinical Implications: AI-ECG could pre-screen for LV systolic dysfunction to prioritize echocardiography, monitor high-risk populations, and support remote/low-resource settings.
Key Findings
- ECG-only AI model estimated LVEF with MAE 7.71% (RMSE 10.36%); hybrid model had MAE 7.84%.
- Personalized AI markedly improved accuracy (MAE 5.98% ECG-only; 6.75% hybrid).
- LV systolic dysfunction (LVEF ≤40%) detected with AUC 0.88, sensitivity 0.92, and NPV 0.98.
Methodological Strengths
- Very large real-world dataset (191,941 patients; 236,623 ECG/TTE pairs).
- Personalized modeling with uncertainty quantification and performance benchmarking.
Limitations
- Retrospective design; generalizability beyond the contributing health system requires external, prospective validation.
- Model interpretability at individual feature level and impact on clinical outcomes were not assessed.
Future Directions: Prospective, multi-center validation; integration into clinical pathways to test impact on time-to-diagnosis and outcomes; fairness and subgroup performance audits.
Left-ventricular (LV) ejection fraction (LVEF) is a fundamental measure of cardiac function, typically assessed with resource-intensive imaging techniques, such as transthoracic echocardiography (TTE). We evaluated the electrocardiogram (ECG) as an alternative, easily accessible data to estimate LVEF in a large cohort of 191,941 patients, comprising 236,623 ECG/TTE pairs. Using either the ECG data alone or with structured features, we developed convolutional and probabilistic neural network models to estimate LVEF and quantify its uncertainty. The ECG-only model achieved a mean-absolute-error (MAE) of 7.71% and a root-mean-square-error (RMSE) of 10.36%, while the hybrid model achieved an MAE of 7.84% and an RMSE of 10.52%. Personalized models significantly improved performance, achieving MAEs of 5.98% (ECG-only) and 6.75% (hybrid). LV systolic dysfunction (LVEF ≤ 40%) was identified with an AUC of 0.88, sensitivity of 0.92 and negative predictive value of 0.98. The presented models demonstrated excellent performance in estimating LVEF and screening of LV systolic dysfunction.